Alkem Laboratories receives 7 observations following US FDA inspection at Daman facility
The US regulator conducted an inspection at the Amaliya manufacturing plant between April 20 and May 1, 2026
The US regulator conducted an inspection at the Amaliya manufacturing plant between April 20 and May 1, 2026
Notice of Compliance from Health Canada enables marketing authorisation for cancer biosimilar in Canadian market
Market authorization for generic GLP-1 therapy strengthens company’s diabetes portfolio in Canada
The Puducherry facility, dedicated to Ibuprofen and its derivatives, is equipped with advanced infrastructure to serve both domestic and international markets
Patalganga plant received zero observation from USFDA earlier
Approval for generic Semaglutide Injection strengthens CDMO partnership, enabling scalable supply from OneSource’s US FDA-approved Bengaluru facility
After Phase 3 results show major hair regrowth gains
The submission is backed by positive results from the Phase 3 AFFIRM study
The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Gilenya Capsules, 0.5 mg of Novartis Pharmaceuticals Corporation (Novartis)
The approval makes Cipla’s product the first AB-rated generic therapeutic equivalent of Ventolin HFA
Approval for Albuterol Sulfate inhalation aerosol enables Cipla Limited to enter the $1.5 billion U.S. albuterol market
The product is approved as bioequivalent to Xigduo XR for the indications outlined in the reference drug’s labelling
The newly approved pill combines 100 mg of doravirine with 0.25 mg of islatravir
The approval, following a positive recommendation from the European Medicines Agency’s CHMP, makes the vaccine valid across all 27 EU member states
OneSource is the contract development and manufacturing organization (CDMO) partner for this product
Shift from approvals to digital intimation via NSWS portal aims to cut timelines and boost innovation in early-stage drug development
The approved product is a generic version of Ravicti, originally developed and marketed by Horizon Therapeutics
The drug is designed to provide temporary relief from cough caused by throat and bronchial irritation
The company stated that it will work closely with the regulator to address the observations within the stipulated timeframe
Subscribe To Our Newsletter & Stay Updated